Coverage Initiated on Immunotherapy Developer with Phase 3 Lead Asset
Source: Streetwise Reports  (6/20/18)
A B. Riley FBR report provided an overview of this life sciences firm. More >

Transfusion Medicine Biotech Hits Target on Road to Commercialization
Source: Streetwise Reports  (6/20/18)
A BTIG report reviewed the news recently announced by this supplier of blood grouping reagents and control products. More >

Biotech Targeting Alzheimer's Disease Advances Toward Phase 1
Source: Streetwise Reports  (6/13/18)
Having secured a manufacturing partner for its proprietary antibody candidate, this precision medicine company charts progress toward a Phase 1 trial in Alzheimer's disease. More >

Biotech Releases 'Unequivocally Positive' Topline NASH Study Results
Source: Streetwise Reports  (6/13/18)
An H.C. Wainwright & Co. report relayed the highlights of the new trial data from this Israel-based firm. More >

Biotech Consolidates Shares in Preparation for NASDAQ Listing
Source: Streetwise Reports  (6/5/18)
A Canaccord Genuity analyst provided an update on this late-stage Canadian life sciences firm targeting metastatic breast cancer. More >

Coverage Initiated on Developer of Women's Reproductive Health Products
Source: Streetwise Reports  (5/30/18)
A ROTH Capital Partners research report outlined the key drivers of the investment thesis for this firm. More >

Biotech Announces Encouraging HIV Vaccine Results
Source: Streetwise Reports  (5/23/18)
Ram Selvaraju, an analyst with H.C. Wainwright & Co., explained the recently released data from a study of one of this immunotherapy firm's therapeutics.
More >

Shovelnose Delivers Gold to Westhaven
Source: Bob Moriarty for Streetwise Reports  (5/17/18)
Bob Moriarty of 321 Gold profiles a company that holds a large land position in the "most unexplored gold belt in British Columbia." More >

Cancer in the Crosshairs: IMV Looks to Deliver Immunotherapy a New Way
Source: Streetwise Reports  (5/16/18)
In this interview with The Life Sciences Report, IMV Inc.'s CEO Fred Ors and Pierre Labbè, chief financial officer, describe the innovative immunotherapy platform technology that has attracted partnerships with big pharma, prompted reorganization of the company, and holds long-term promise for cancer patients. More >

Biotech's Launch of Pain Product Shows Encouraging Early Metrics
Source: Streetwise Reports  (5/12/18)
Francois Brisebois, an analyst with Laidlaw & Co., reviewed this firm's progress since commercially debuting its primary asset.
More >

Concurrent Milestones for Biotech Set to Occur 'on the Horizon'
Source: Streetwise Reports  (5/9/18)
Analyst Douglas Loe with Echelon Wealth Partners discussed this immunotherapy developer's recent and upcoming news. More >

Cell Therapy Firm Finalizing $5.1M Strategic Investment and Partnership with Chinese Company
Source: Streetwise Reports  (5/9/18)
The terms of a proposed agreement between this cell therapy company and YOFOTO, a Chinese health and consumer products company, have been revised and will result in a $5.1 million investment. More >

What Stephen Hawking Missed: Small Biotechs Developing Promising Cell Therapies for Devastating Disease
Source: Streetwise Reports  (5/2/18)
In the second of a two-part series exploring the disruptive cell therapy space, Maxim Group analyst Jason McCarthy takes a look at small-cap companies targeting big-ticket indications and their potential to drive blockbuster value for both patients and investors. More >

Risk Versus Reward: The Value of Cell Therapy for Patients and Investors
Source: Streetwise Reports  (4/25/18)
The cell therapy space, encompassing disruptive new treatment including stem cell therapy, immunotherapy and gene editing, has begun to mature, with a handful of product approvals and others in late-stage development. In the first of a two-part series examining the disruptive technology, Maxim Group analyst Jason McCarthy exposes the upsides and downsides of the space, and the companies at its forefront. More >

Analyst Sees Tenbagger in Biotech Firm with 'Favorable Updates'
Source: Streetwise Reports   (4/24/18)
Ram Selvaraju, an analyst with H.C. Wainwright & Co., relayed the most recent news concerning this firm's drug candidate. More >

Biotech Round-Up: M&As, Financings and Immuno-Oncology
Source: John McCamant for Streetwise Reports  (4/18/18)
John McCamant, editor of Medical Technology Stock Letter, reviews biotech M&A and financings, and discusses one company that is expanding its immuno-oncology pipeline. More >

Major Cannabis Player Sees Florida Sales Surge Over 250% and Will Acquire 75% Ownership in Massachusetts Deal
Source: Streetwise Reports  (4/17/18)
A medicinal cannabis company has seen its Florida sales increase 253%, and the company just gained 75% control over a Massachusetts-based dispensary operation, expanding its influence in the medicinal marijuana industry. More >

Biotech Gets Cashed Up Ahead of Pivotal Phase 3 Readouts
Source: Streetwise Reports  (4/17/18)
Ram Selvaraju, an analyst with H.C. Wainwright & Co., discussed the capital raise and upcoming clinical trial data.

More >

Biotech with Deep Pipeline, 'Abundant' Upcoming Catalysts Named Top Pick
Source: Streetwise Reports  (4/11/18)
Douglas Loe, an analyst with Echelon Wealth Partners, made the case for why this biopharmaceutical company merits this status.
More >

Biotech Announces Positive Topline Data in Tourette Syndrome
Source: Streetwise Reports  (4/11/18)
Francois Brisebois, a Laidlaw & Co. analyst, reviewed the recently released study results and upcoming catalysts. More >

RNAi Therapeutics Developer Reports Positive Amyloidosis Data
Source: Streetwise Reports  (4/4/18)
Michael King, an analyst with JMP Securities, reported the new results that this biotech presented in March. More >

CMS Unexpectedly Issues Product Billing Code to Biotech
Source: Streetwise Reports  (4/4/18)
Francois Brisebois, an analyst with Laidlaw & Co., shared and weighed in on the latest news regarding this biopharmaceutical firm.
More >

Biotech Delivers 'Excellent' Phase 2 Data
Source: John McCamant for Streetwise Reports  (4/3/18)
John McCamant, editor of Medical Technology Stock Letter, discusses a biotech with data that he views as positive from a Phase 2 LDL cholesterol lowering trial. More >

Medical Device Firm Posts 'Strong Performance' Globally in Q4/17
Source: Streetwise Reports   (3/28/18)
The company performed strongly in the U.S. and the Asia Pacific region. More >

Regrouped Biotech's Stock Price Could See Fifteenfold Increase
Source: Streetwise Reports  (3/28/18)
A recent conference call provided clinical and financial updates. More >